Drug Trial Radar · NCT03636269
CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Last checked: Nov 19, 2026Latest source record: Apr 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
473
Actual
Start
Jul 17, 2018
Primary completion
Mar 30, 2020
Study completion Mar 30, 2020
Sponsor
- Lead sponsor
- Cara Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 17, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, international study to evaluate the safety and efficacy of intravenous (IV) CR845 at a dose of 0.5 mcg/kg administered after each dialysis session. The study includes a 12-week randomized, double-blind, placebo-controlled Phase and a 52-week Open-label Extension Phase.
Conditions
- Uremic Pruritus
Interventions
CR845 0.5 mcg/kgDrug
IV CR845 0.5 mcg/kg administered three times/week
PlaceboDrug
IV placebo administered three times/week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline ≥3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity Numerical Rating Scale (NRS) Score at Week 12Time frame: Week 12
Locations
92 sites in 11 countries. Site status is shown where the registry gives one.
Cara Therapeutics Study Site
Chula Vista, California
Cara Therapeutics Study Site
Fountain Valley, California
Cara Therapeutics Study Site
Northridge, California
Cara Therapeutics Study Site
Riverside, California
Cara Therapeutics Study Site 2
San Dimas, California
Cara Therapeutics Study Site
San Dimas, California
Cara Therapeutics Study Site
Westminster, Colorado
Cara Therapeutics Study Site
Hialeah, Florida
Cara Therapeutics Study Site
Miami Gardens, Florida
Cara Therapeutics Study Site
Orlando, Florida
Cara Therapeutics Study Site
Athens, Georgia
Cara Therapeutics Study Site
Macon, Georgia
Cara Therapeutics Study Site
Baton Rouge, Louisiana
Cara Therapeutics Study Site
Brockton, Massachusetts
Cara Therapeutics Study Site
Kalamazoo, Michigan
Cara Therapeutics Study Site
Roseville, Michigan
Cara Therapeutics Study Site
Saint Clair, Michigan
Cara Therapeutics Study Site
Tupelo, Mississippi
Cara Therapeutics Study Site
St Louis, Missouri
Cara Therapeutics Study Site
Clifton, New Jersey
Cara Therapeutics Study Site
Somerville, New Jersey
Cara Therapeutics Study Site
Albuquerque, New Mexico
Cara Therapeutics Study Site
Long Island City, New York
Cara Therapeutics Study Site
Austin, Texas
Cara Therapeutics Study Site
Dallas, Texas
Cara Therapeutics Study Site
McAllen, Texas
Cara Therapeutics Study Site
San Antonio, Texas
Cara Therapeutics Study Site
St. George, Utah
Cara Therapeutics Study Site
Roanoke, Virginia
Cara Therapeutics Study Site
Adelaide, Australia
Cara Therapeutics Study Site
Camperdown, New South Wales, Australia
Cara Therapeutics Study Site
Concord, New South Wales, Australia
Cara Therapeutics Study Site
Wahroonga, New South Wales, Australia
Cara Therapeutics Study Site
Westmead, New South Wales, Australia
Cara Therapeutics Study Site
Launceston, Tasmania, Australia
Cara Therapeutics Study Site
Clayton, Victoria, Australia
Cara Therapeutics Study Site
Heidelberg, Victoria, Australia
Cara Therapeutics Study Site
St Albans, Victoria, Australia
Cara Therapeutics Study Site
Halifax, Nova Scotia, Canada
Cara Therapeutics Study Site
Oshawa, Ontario, Canada
Showing 40 of 92 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.